These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Production of Recombinant Alpha-Synuclein: Still No Standardized Protocol in Sight. Al-Azzani M; König A; Outeiro TF Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204823 [TBL] [Abstract][Full Text] [Related]
6. Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein. Landeck N; Strathearn KE; Ysselstein D; Buck K; Dutta S; Banerjee S; Lv Z; Hulleman JD; Hindupur J; Lin LK; Padalkar S; Stanciu LA; Lyubchenko YL; Kirik D; Rochet JC Mol Neurodegener; 2020 Sep; 15(1):49. PubMed ID: 32900375 [TBL] [Abstract][Full Text] [Related]
7. Environmental and genetic factors support the dissociation between α-synuclein aggregation and toxicity. Villar-Piqué A; Lopes da Fonseca T; Sant'Anna R; Szegö ÉM; Fonseca-Ornelas L; Pinho R; Carija A; Gerhardt E; Masaracchia C; Abad Gonzalez E; Rossetti G; Carloni P; Fernández CO; Foguel D; Milosevic I; Zweckstetter M; Ventura S; Outeiro TF Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6506-E6515. PubMed ID: 27708160 [TBL] [Abstract][Full Text] [Related]
8. Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. Lázaro DF; Rodrigues EF; Langohr R; Shahpasandzadeh H; Ribeiro T; Guerreiro P; Gerhardt E; Kröhnert K; Klucken J; Pereira MD; Popova B; Kruse N; Mollenhauer B; Rizzoli SO; Braus GH; Danzer KM; Outeiro TF PLoS Genet; 2014 Nov; 10(11):e1004741. PubMed ID: 25393002 [TBL] [Abstract][Full Text] [Related]
9. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease. Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782 [TBL] [Abstract][Full Text] [Related]
10. Hsp70 chaperone blocks α-synuclein oligomer formation via a novel engagement mechanism. Tao J; Berthet A; Citron YR; Tsiolaki PL; Stanley R; Gestwicki JE; Agard DA; McConlogue L J Biol Chem; 2021; 296():100613. PubMed ID: 33798554 [TBL] [Abstract][Full Text] [Related]
11. Mechanisms of alpha-synuclein toxicity: An update and outlook. Brás IC; Xylaki M; Outeiro TF Prog Brain Res; 2020; 252():91-129. PubMed ID: 32247376 [TBL] [Abstract][Full Text] [Related]
12. Traffic jams and the complex role of α-Synuclein aggregation in Parkinson disease. Gonçalves SA; Outeiro TF Small GTPases; 2017 Apr; 8(2):78-84. PubMed ID: 27314512 [TBL] [Abstract][Full Text] [Related]
20. Do Lewy bodies contain alpha-synuclein fibrils? and Does it matter? A brief history and critical analysis of recent reports. Lashuel HA Neurobiol Dis; 2020 Jul; 141():104876. PubMed ID: 32339655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]